Personal information

No personal information available

Activities

Collapse all

Works (8)

A Novel Step‐Up Dosage Regimen for Enhancing the Benefit‐to‐Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma

Clinical Pharmacology & Therapeutics
2025-02 | Journal article
DOI: 10.1002/cpt.3445
Contributors: Chi‐Chung Li; Brendan Bender; Justin Wilkins; Feifei Li; David C. Turner; Bei Wang; Rong Deng; Shweta Vadhavkar; Zao Li; Antonia Kwan et al.
Source: check_circle
Crossref

Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies

Clinical Cancer Research
2025-01-17 | Journal article
DOI: 10.1158/1078-0432.CCR-24-2247
Contributors: Kendra K. Radtke; Brendan C. Bender; Zao Li; David C. Turner; Sumedha Roy; Anton Belousov; Chi-Chung Li
Source: check_circle
Crossref

Data from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies

2025-01-17 | Preprint
DOI: 10.1158/1078-0432.c.7631041
Contributors: Kendra K. Radtke; Brendan C. Bender; Zao Li; David C. Turner; Sumedha Roy; Anton Belousov; Chi-Chung Li
Source: check_circle
Crossref

Supplementary Figure S1 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies

2025-01-17 | Preprint
DOI: 10.1158/1078-0432.28227556
Contributors: Kendra K. Radtke; Brendan C. Bender; Zao Li; David C. Turner; Sumedha Roy; Anton Belousov; Chi-Chung Li
Source: check_circle
Crossref

Supplementary Figure S2 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies

2025-01-17 | Preprint
DOI: 10.1158/1078-0432.28227553
Contributors: Kendra K. Radtke; Brendan C. Bender; Zao Li; David C. Turner; Sumedha Roy; Anton Belousov; Chi-Chung Li
Source: check_circle
Crossref

Supplementary Table S1 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies

2025-01-17 | Preprint
DOI: 10.1158/1078-0432.28227550
Contributors: Kendra K. Radtke; Brendan C. Bender; Zao Li; David C. Turner; Sumedha Roy; Anton Belousov; Chi-Chung Li
Source: check_circle
Crossref

Supplementary Table S2 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies

2025-01-17 | Preprint
DOI: 10.1158/1078-0432.28227547
Contributors: Kendra K. Radtke; Brendan C. Bender; Zao Li; David C. Turner; Sumedha Roy; Anton Belousov; Chi-Chung Li
Source: check_circle
Crossref

Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B‐cell non‐Hodgkin lymphoma

Clinical and Translational Science
2024-06 | Journal article
DOI: 10.1111/cts.13825
Contributors: Brendan Bender; Chi‐Chung Li; Mathilde Marchand; David C. Turner; Feifei Li; Shweta Vadhavkar; Bei Wang; Rong Deng; James Lu; Jin Jin et al.
Source: check_circle
Crossref
How many people are using ORCID?